<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073811435829</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073811435829</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Topical Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Epilepsy in Children—When Should We Think Neurometabolic Disease?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dhamija</surname>
<given-names>Radhika</given-names>
</name>
<degrees>MBBS</degrees>
<xref ref-type="aff" rid="aff1-0883073811435829">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Patterson</surname>
<given-names>Marc C.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073811435829">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wirrell</surname>
<given-names>Elaine C.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073811435829">1</xref>
<xref ref-type="corresp" rid="corresp1-0883073811435829"/>
</contrib>
</contrib-group>
<aff id="aff1-0883073811435829">
<label>1</label>Division of Child and Adolescent Neurology, Mayo Clinic Children’s Center, Rochester, MN, USA</aff>
<author-notes>
<corresp id="corresp1-0883073811435829">Elaine C. Wirrell, MD, Division of Child and Adolescent Neurology, Mayo Building, 16th floor, Mayo Clinic, 200 First Street SW, Rochester, MN 55905 Email: <email>wirrell.elaine@mayo.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>5</issue>
<fpage>663</fpage>
<lpage>671</lpage>
<history>
<date date-type="received">
<day>20</day>
<month>12</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>12</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Seizures are often the first manifestation of central nervous system dysfunction and are common in many inborn errors of metabolism, especially in neonates, infants, and children. A high index of suspicion is required to diagnose inborn errors of metabolism as the cause of seizures. It is also important to recognize these metabolic disorders early, as specific disease-modifying treatments are available for some with favorable long-term outcomes. This review discusses the classification of metabolic disorders as a cause of seizures based on pathogenesis and age and proposes a tiered approach for cost-effective diagnosis of metabolic disorders.</p>
</abstract>
<kwd-group>
<kwd>epilepsy</kwd>
<kwd>pathogenesis metabolism</kwd>
<kwd>seizures</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Seizures are common manifestations of many inborn errors of metabolism, especially in neonates, infants, and children. Inborn errors of metabolism are rare as individual entities, but their estimated combined incidence is 1 in 3000 live births.<sup>
<xref ref-type="bibr" rid="bibr1-0883073811435829">1</xref>,<xref ref-type="bibr" rid="bibr2-0883073811435829">2</xref>
</sup> The reader is referred to the Orphanet study of the prevalence of rare diseases for more detailed and current information regarding the prevalence and relative frequency of inborn errors of metabolism compared with other rare diseases (<ext-link ext-link-type="uri" xlink:href="http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf">http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf</ext-link>). It is important to recognize these metabolic disorders early because specific disease-modifying treatments are available for some (such as the ketogenic diet for glucose transporter-1 deficiency). Even when specific disease-modifying therapy is lacking, early diagnosis provides the opportunity for timely genetics counseling. Parents are thus given the opportunity to avoid giving birth to multiple siblings with severe illness, and the diagnosis allows more accurate prognostication for the index case. Seizures in inborn errors of metabolism may be a constant feature in some disorders (such as the neuronal ceroid lipofuscinosis) or may occur only during periods of acute decompensation in others (eg, urea cycle defects, organic acidemias).</p>
<p>Seizures associated with inborn errors of metabolism can be classified in several ways, including pathogenesis (<xref ref-type="table" rid="table1-0883073811435829">Table 1</xref>), age of onset (<xref ref-type="table" rid="table2-0883073811435829">Table 2</xref>), and seizure semiology. Age of onset and seizure semiology may be helpful in predicting certain underlying inborn errors of metabolism but are not very specific.</p>
<table-wrap id="table1-0883073811435829" position="float">
<label>Table 1.</label>
<caption>
<p>Classification of Metabolic Epilepsies According to Their Pathogenesis</p>
</caption>
<graphic alternate-form-of="table1-0883073811435829" xlink:href="10.1177_0883073811435829-table1.tif"/>
<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excessive excitation of neurons: Toxic effects due to excessive accumulation of certain metabolites</td>
<td>Aminoacidopathies Organic acidurias Biotinidase deficiency Urea cycle defects Nonketotic hyperglycinemia</td>
</tr>
<tr>
<td>Deficient inhibition of neurons: Vitamin or cofactor deficiency</td>
<td>Pyridoxine dependent Pyridoxine phosphate dependent Folinic acid responsive γ-Aminobutyric acid transaminase deficiency Succinic semialdehyde dehydrogenase deficiency Aromatic L-amino acid decarboxylase deficiency </td>
</tr>
<tr>
<td>Energy deficiency</td>
<td>Glucose transporter-1 deficiency Mitochondrial disorders Creatine deficiency Congenital disorders of glycosylation</td>
</tr>
<tr>
<td>Neuronal dysfunction associated with structural changes: Storage disorders Metabolic disorders associated with brain malformation</td>
<td>Lysosomal disorders Peroxisomal disorders Congenital disorders of glycosylation</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table2-0883073811435829" position="float">
<label>Table 2.</label><caption>
<p>'Classification of Metabolic Epilepsies According to Age of Onset</p>
</caption>
<graphic alternate-form-of="table2-0883073811435829" xlink:href="10.1177_0883073811435829-table2.tif"/>
<table>
<tbody>
<tr>
<td>Neonatal seizures</td>
<td>Aminoacidopathies, organic acidurias, urea cycle defects, nonketotic hyperglycinemia, glucose transporter-1 deficiency, sulfite oxidase deficiency, mitochondrial disorders, biotinidase deficiency, pyridoxine dependent, pyridoxine phosphate dependent, folinic acid responsive, neonatal peroxisomal disorders, aromatic L-amino acid decarboxylase deficiency </td>
</tr>
<tr>
<td>Early infantile–onset seizures</td>
<td>Lysosomal storage disorders (gangliosidoses, neuronal ceroid lipofuscinoses), mitochondrial disorders, biotinidase deficiency, glucose transporter-1</td>
</tr>
<tr>
<td>Late infantile–onset seizures</td>
<td>Lysosomal storage disorders (gangliosidoses, neuronal ceroid lipofuscinoses, Gaucher type 2 and 3, Niemann-Pick A and C), mitochondrial disorders, congenital disorders of glycosylation</td>
</tr>
<tr>
<td>Child- and adolescent-onset seizures</td>
<td>Lysosomal storage disorders (neuronal ceroid lipofuscinoses, gangliosidoses, Gaucher type 2 and 3, Niemann-Pick A and C), Lafora disease, congenital disorders of glycosylation</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Several pathophysiological mechanisms may explain the occurrence of seizures in metabolic diseases. Seizures could result from production or accumulation of excessive excitatory mediators, deficiency of inhibitory mediators, or deficient adenosine triphosphate (ATP) generation. Neuronal dysfunction (and ultimately death) and secondary inflammation occur in storage diseases. Multiple factors are likely to be operative in many inborn errors of metabolism.</p>
<p>Careful and comprehensive clinical assessment, neuroimaging studies, electroencephalography (EEG), and histopathological information from selected biopsies help to establish the diagnosis. Clues to the underlying diagnosis differ according to age at presentation and are discussed below.</p>
<sec id="section1-0883073811435829">
<title>When to Suspect Metabolic Epilepsy in Neonates</title>
<list list-type="order">
<list-item>
<p>Seizures and encephalopathy several days postpartum following normal pregnancy and delivery, absent postpartum complications. Seizures generally present after the first 1 to 2 days of life because the maternal metabolic machinery that was able to compensate for the metabolic deficiency of the neonate is no longer available after birth. When neonates with severely defective metabolic pathways are exposed to a substrate load (usually the first feeding, or the catabolic stress of infection), they decompensate.</p>
</list-item>
<list-item>
<p>Family history of a sibling dying of an unknown cause or consanguinity in the family</p>
</list-item>
<list-item>
<p>Peculiar odor of the body fluids (eg, maple syrup urine disease, isovaleric acidemia)</p>
</list-item>
<list-item>
<p>Macrocephaly (eg, glutaric aciduria-1, Canavan disease) or microcephaly</p>
</list-item>
<list-item>
<p>History of hydrops fetalis (eg, many storage diseases)<sup>
<xref ref-type="bibr" rid="bibr3-0883073811435829">3</xref>
</sup>
</p>
</list-item>
<list-item>
<p>Respiratory distress that cannot be explained by pulmonary or cardiac abnormalities (eg, urea cycle defect, organic acidurias)</p>
</list-item>
<list-item>
<p>Cardiomyopathy (eg, mitochondrial disease, congenital disorders of glycosylation)</p>
</list-item>
<list-item>
<p>Organomegaly (eg, storage diseases, peroxisomal disorders, congenital disorders of glycosylation)</p>
</list-item>
<list-item>
<p>Dysmorphism (eg, neonatal peroxisomal disorders, congenital disorders of glycosylation)</p>
</list-item>
<list-item>
<p>Hematological abnormalities (eg, propionic aciduria, methylmalonic aciduria, isovaleric aciduria, congenital disorders of glycosylation)</p>
</list-item>
<list-item>
<p>Dermatological abnormalities (eg, biotinidase deficiency)</p>
</list-item>
<list-item>
<p>Characteristic magnetic resonance imaging (MRI) abnormalities (eg, mitochondrial diseases, glutaric aciduria-1, storage disorders, congenital disorders of glycosylation) or magnetic resonance spectroscopy abnormalities (eg, abnormal lactate peak in mitochondrial diseases, glycine peak in nonketotic hyperglycinemia)</p>
</list-item>
<list-item>
<p>Characteristic EEG abnormalities (eg, worsening before meals in glucose transporter-1, burst suppression in nonketotic hyperglycinemia)</p>
</list-item>
</list>
</sec>
<sec id="section2-0883073811435829">
<title>When to Suspect Metabolic Epilepsy in Infancy and Childhood</title>
<list list-type="order">
<list-item>
<p>Family history of a sibling dying of an unknown cause</p>
</list-item>
<list-item>
<p>Global psychomotor retardation that can be progressive or regression in milestones with no other potential explanation</p>
</list-item>
<list-item>
<p>Multisystemic involvement (eg, mitochondrial disease, storage diseases, congenital disorders of glycosylation)</p>
</list-item>
<list-item>
<p>Dermatological abnormalities (eg, biotinidase deficiency, mitochondrial diseases, some lysosomal storage disorders)</p>
</list-item>
<list-item>
<p>Characteristic MRI abnormalities (eg, mitochondrial diseases, glutaric aciduria-1, storage disorders, congenital disorders of glycosylation)</p>
</list-item>
<list-item>
<p>Episodes of acute metabolic decompensation (eg, mitochondrial disease, organic acidurias, congenital disorders of glycosylation)</p>
</list-item>
<list-item>
<p>Dysmorphism (eg, storage diseases, peroxisomal diseases, congenital disorders of glycosylation)</p>
</list-item>
<list-item>
<p>Characteristic ophthalmological findings (eg, storage disease, mitochondrial diseases)</p>
</list-item>
<list-item>
<p>Characteristic EEG abnormalities (eg, epilepsia partialis continua in Alpers syndrome)</p>
</list-item>
</list>
</sec>
<sec id="section3-0883073811435829">
<title>Diagnostic Laboratory Tests</title>
<p>Most metabolic diseases cannot be cured, but disease-modifying therapy is available in an increasing number of disorders. All children with inborn errors of metabolism benefit from careful medical management, regardless of the availability of disease-modifying therapy. The first priority is to diagnose those metabolic diseases for which disease-modifying therapy is available.</p>
<p>Diagnostic testing should be performed in a stepwise fashion for cost-effectiveness. We recommend a tiered approach listed below:</p>
<sec id="section4-0883073811435829">
<title>First-Tier Tests</title>
<list list-type="bullet">
<list-item>
<p>Blood: Blood gas analysis with electrolytes (anionic gap), glucose, lactate, pyruvate, ammonia, amino acids, long-chain fatty acids, carnitine, acylcarnitine, liver function tests, serum biotinidase activity, carbohydrate deficient transferrin</p>
</list-item>
<list-item>
<p>Urine ketones, acylglycines, orotic acid</p>
</list-item>
<list-item>
<p>Cerebrospinal fluid glucose, lactate, amino acids</p>
</list-item>
<list-item>
<p>Ketoacidosis and hypoglycemia: aminoacidopathies, organic acidurias</p>
</list-item>
<list-item>
<p>Low biotinidase activity with or without abnormal organic acids in urine: biotinidase deficiency</p>
</list-item>
<list-item>
<p>Lactic acidosis and elevated cerebrospinal fluid lactate: disorder of pyruvate metabolism or the respiratory chain (plus some organic acidemias)</p>
</list-item>
<list-item>
<p>Markedly elevated ammonia, elevated orotic acid, and respiratory alkalosis: urea cycle disorder</p>
</list-item>
<list-item>
<p>Low ketones and hypoglycemia: disorders of mitochondrial fatty acid oxidation, congenital disorders of glycosylation</p>
</list-item>
<list-item>
<p>Low cerebrospinal fluid–serum glucose ratio and low cerebrospinal fluid lactate: glucose transporter-1 deficiency</p>
</list-item>
<list-item>
<p>Elevated cerebrospinal fluid glycine: nonketotic hyperglycinemia</p>
</list-item>
<list-item>
<p>Low cerebrospinal fluid and serum serine: defects of serine biosynthesis</p>
</list-item>
<list-item>
<p>Abnormal carbohydrate deficient transferrin: congenital disorder of glycosylation</p>
</list-item>
<list-item>
<p>Confirmatory tests for above diagnosis are available clinically. See discussion below.</p>
</list-item>
</list>
</sec>
<sec id="section5-0883073811435829">
<title>Second-Tier Tests</title>
<list list-type="bullet">
<list-item>
<p>Urine: guanidino compounds, α-aminoadipic semialdehyde, purines and pyrimidines</p>
</list-item>
<list-item>
<p>Cerebrospinal fluid: neurotransmitters, folinic acid (5-methyltetrahydrofolate)</p>
</list-item>
<list-item>
<p>Magnetic resonance spectroscopy</p>
</list-item>
<list-item>
<p>Increased guanidino compounds in the urine: disorder of creatine metabolism</p>
</list-item>
</list>
</sec>
<sec id="section5a-0883073811435829">
<title>Interpretation</title>
<list list-type="bullet">
<list-item>
<p>Increased α-aminoadipic semialdehyde in the urine: pyridoxine-dependent seizures</p>
</list-item>
<list-item>
<p>Abnormal purines and pyrimidines: disorders of purine and pyrimidine metabolism (eg, adenylosuccinate lyase deficiency)</p>
</list-item>
<list-item>
<p>Magnetic resonance spectroscopy: loss of creatine peak: disorder of creatine metabolism</p>
</list-item>
<list-item>
<p>Confirmatory tests for the above diagnoses are available clinically. See discussion below.</p>
</list-item>
</list>
</sec>
<sec id="section6-0883073811435829">
<title>Third-Tier Tests </title>
<p>
<list list-type="bullet">
<list-item>
<p>Urine: mucopolysaccharide and oligosaccharide screening</p>
</list-item>
<list-item>
<p>Leucocyte enzyme analysis for specific enzyme defects</p>
</list-item>
<list-item>
<p>Skin and muscle biopsy for storage disorders, mitochondrial disorders</p>
</list-item>
<list-item>
<p>Specialized molecular and genetic tests for specific diagnosis</p>
</list-item>
</list>
Classification of inborn errors of metabolisms based on pathogenesis is discussed in detail in this review. Although multiple pathogenic mechanisms are likely involved in many metabolic diseases, they can be divided into broad categories as discussed below.</p>
</sec>
</sec>
<sec id="section7-0883073811435829">
<title>Excessive Excitation of Neurons: Toxic Effects Due to Excessive Accumulation of Certain Metabolites</title>
<p>The following families of disorders result from enzyme deficiencies and produce their effects by accumulation of substrates proximal to the block in the metabolic pathway. In some cases, the toxins arise through activation of alternate metabolic pathways.</p>
<sec id="section8-0883073811435829">
<title>Urea Cycle Defect</title>
<p>The classic presentation of defects in the urea cycle is with hyperammonemic encephalopathy in the first week of life. The combination of a high serum ammonia level, respiratory alkalosis, normal serum glucose, and normal anion gap suggests a urea cycle defect. Seizures are common at onset with varying degrees of encephalopathy. The EEG typically shows slow waves and may demonstrate burst suppression in severe cases. Mortality is high during the acute phase, but if metabolic control is achieved during this phase, long-term epilepsy control is not usually difficult.<sup>
<xref ref-type="bibr" rid="bibr4-0883073811435829">4</xref>
</sup>
</p>
</sec>
<sec id="section9-0883073811435829">
<title>Nonketotic Hyperglycinemia</title>
<p>Nonketotic hyperglycinemia, also known as glycine encephalopathy, is an autosomal-recessive metabolic disorder characterized by the accumulation of glycine in the brain due to a defect in various components of mitochondrial glycine cleavage enzyme system. The neonatal form presents in the first few days of life with progressive lethargy, encephalopathy, hypotonia, hiccups, and seizures and progresses to central apnea and often death. Surviving infants often have profound developmental delay and intractable seizures. The infantile form presents in the first few months of life and is also characterized by hypotonia, developmental delay, and seizures. An increased cerebrospinal fluid glycine level (typically 20-30 times the normal level) along with an elevated ratio of cerebrospinal fluid to plasma glycine suggests the diagnosis. The elevated ratio of cerebrospinal fluid to serum glycine (&gt;0.08) confirms the diagnosis of nonketotic hyperglycinemia. Atypical patients can have ratios between 0.03 and 0.08. Enzymatic confirmation is possible by measurement of glycine cleavage enzyme activity in a liver biopsy sample and is clinically available. There are 3 genes known to be associated with nonketotic hyperglycinemia.<sup>
<xref ref-type="bibr" rid="bibr5-0883073811435829">5</xref>
</sup>
</p>
<p>The initial EEG typically shows a burst-suppression pattern that evolves into hypsarrhythmia and/or multifocal spikes over the next few months. Magnetic resonance imaging can be normal or show agenesis of the corpus callosum. Delayed myelination can be seen later in life. A glycine peak on magnetic resonance spectroscopy is seen in the most severely affected infants and carries a poor prognosis.<sup>
<xref ref-type="bibr" rid="bibr6-0883073811435829">6</xref>
</sup>
</p>
<p>No consistently effective treatment exists for this disorder. Therapy is focused on managing seizures by using sodium benzoate to reduce plasma concentration of glycine. N-methyl-D-aspartate (NMDA) receptor antagonists (ketamine, dextromethorphan, felbamate, topiramate) are also used in this condition.<sup>
<xref ref-type="bibr" rid="bibr7-0883073811435829">7</xref>
</sup>
</p>
</sec>
<sec id="section10-0883073811435829">
<title>Organic Acidurias</title>
<p>Seizures in organic acidurias typically occur at presentation or during acute decompensation, as, for example, in methylmalonic acidemia, isovaleric acidemia, propionic acidemia, and glutaric aciduria, type 1. The diagnosis is based on a characteristic pattern of metabolite excretion. Permanent neurological damage is common in children with delayed diagnosis or severe neurological presentations with ongoing seizures in survivors.<sup>
<xref ref-type="bibr" rid="bibr8-0883073811435829">8</xref>,<xref ref-type="bibr" rid="bibr9-0883073811435829">9</xref>
</sup>
</p>
</sec>
<sec id="section11-0883073811435829">
<title>Biotinidase Deficiency</title>
<p>Biotin is a cofactor for several carboxylases. Endogenous recycling of biotin is impaired in this disorder. The phenotype includes neonatal and infantile seizures including infantile spasms that are very responsive to small doses of biotin. Hearing loss and optic atrophy are long-term sequelae that do not respond to biotin. Dermatological findings of rash, alopecia, and mucocutaneous candidiasis are frequent. Subcortical cysts have been reported on MRI and are attributed to intracerebral lactic acidosis.<sup>
<xref ref-type="bibr" rid="bibr10-0883073811435829">10</xref>,<xref ref-type="bibr" rid="bibr11-0883073811435829">11</xref>
</sup>
</p>
</sec>
<sec id="section12-0883073811435829">
<title>Aminoacidopathies</title>
<p>Many amino acid disorders are now detected by newborn screening, but screening was originally introduced for phenylketonuria alone. This disorder was a common cause of infantile spasms. Phenylalanine is neurotoxic, and untreated patients have mental retardation and seizures. Maple syrup urine disease is caused by mitochondrial branched-chain ketoacid dehydrogenase complex deficiency leading to accumulation of branched-chain amino acids.<sup>
<xref ref-type="bibr" rid="bibr12-0883073811435829">12</xref>
</sup> Seizures usually accompany acute decompensation of this disease in the neonatal period. It is important to recognize this group of diseases early, as dietary modification can prevent permanent sequelae. Defects of serine biosynthesis amenable to serine supplementation can also present as seizures in neonates.<sup>
<xref ref-type="bibr" rid="bibr13-0883073811435829">13</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section13-0883073811435829">
<title>Deficient Inhibition of Neurons: Vitamin/Cofactor Deficiency</title>
<sec id="section14-0883073811435829">
<title>Pyridoxine-Dependent Seizures</title>
<p>This disorder is an autosomal recessive condition caused by mutation in the ALDH7A1 gene, which encodes antiquitin. This leads to diminished activity of α-aminoadipic semialdehyde dehydrogenase enzyme leading to increased urinary excretion of α-aminoadipic semialdehyde, which serves as a diagnostic test. <sup>
<xref ref-type="bibr" rid="bibr14-0883073811435829">14</xref>
</sup> This intermediate metabolite inactivates pyridoxal 5-phosphate, which is an important enzyme in the synthesis of neurotransmitters. Hence, the phenotype of this entity includes intractable seizures and cognitive dysfunction. All types of seizures, including myoclonic, tonic, and infantile spasms, have been described in this condition. No particular pattern on EEG is specific to this condition, and it can range from normal to a burst suppression pattern.<sup>
<xref ref-type="bibr" rid="bibr15-0883073811435829">15</xref>
</sup> The seizures are usually intractable to conventional antiepileptics but respond to high doses of pyridoxine.<sup>
<xref ref-type="bibr" rid="bibr16-0883073811435829">16</xref>
</sup> Neuroimaging shows thinning of the posterior corpus callosum in many cases.<sup>
<xref ref-type="bibr" rid="bibr17-0883073811435829">17</xref>
</sup>
</p>
</sec>
<sec id="section15-0883073811435829">
<title>Pyridoxine Phosphate–Dependent Seizures</title>
<p>This is a rare autosomal recessive disorder caused by pyridoxamine 5′-phosphate oxidase deficiency, an enzyme that converts pyridoxine phosphate to active cofactor pyridoxal phosphate.<sup>18 </sup>Pyridoxal phosphate is an important cofactor in the synthesis of many neurotransmitters.<sup>19</sup> The phenotype of this disorder includes neonatal and infantile seizures that respond to pyridoxal phosphate but not pyridoxine.<sup>
<xref ref-type="bibr" rid="bibr15-0883073811435829">15</xref>
</sup>
<sup>
<xref ref-type="bibr" rid="bibr20-0883073811435829">20</xref>
</sup> Early treatment is warranted to reduce morbidity and mortality.<sup>
<xref ref-type="bibr" rid="bibr21-0883073811435829">21</xref>
</sup>
</p>
</sec>
<sec id="section16-0883073811435829">
<title>Folinic Acid–Responsive Seizures</title>
<p>This disorder is now known to be allelic to pyridoxine-dependent seizures. Neonates who have seizures that are poorly responsive to pyridoxine but responsive to folinic acid have mutations in the ALDH7A1 gene, which encodes antiquitin. Treatment with both folinic acid and pyridoxine is recommended in such individuals.<sup>
<xref ref-type="bibr" rid="bibr22-0883073811435829">22</xref>
</sup>
</p>
</sec>
<sec id="section17-0883073811435829">
<title>Aromatic L-Amino Acid Decarboxylase Deficiency</title>
<p>Aromatic L-amino acid decarboxylase deficiency is an autosomal recessive disorder of neurotransmitter metabolism important in synthesis of dopamine and serotonin. This presents in the first few months of life with dystonia, athetosis, tongue thrusting, oculogyric crisis, autonomic instability, and seizures. Diagnosis is confirmed by measuring neurotransmitters in the cerebrospinal fluid and aromatic L-amino acid decarboxylase plasma activity level. <sup>
<xref ref-type="bibr" rid="bibr23-0883073811435829">23</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section18-0883073811435829">
<title>Energy Deficiency</title>
<sec id="section19-0883073811435829">
<title>Glucose Transporter-1 Deficiency</title>
<p>Glucose transporter-1 deficiency syndrome is characterized by infantile-onset seizures, acquired microcephaly, and developmental delay (classical phenotype). The diagnosis is established by demonstrating the following</p>
<list list-type="order">
<list-item>
<p>Reduced cerebrospinal fluid glucose concentration (hypoglycorrhachia), less than 45 mg/dL (some cases due to missense mutations or small in-frame deletions may have normal absolute glucose)<sup>
<xref ref-type="bibr" rid="bibr24-0883073811435829">24</xref>
</sup>
</p>
</list-item>
<list-item>
<p>Low ratio of cerebrospinal fluid glucose concentration to blood glucose concentration (∼0.33; normal ratio: 0.65)</p>
</list-item>
<list-item>
<p>Normal blood glucose concentration<sup>
<xref ref-type="bibr" rid="bibr25-0883073811435829">25</xref>
</sup>
</p>
</list-item>
</list>
<p>Molecular genetic testing for <italic>SLC2A1</italic>, the only gene in which mutation is known to be associated with this syndrome, is available on a clinical basis. It is inherited in autosomal dominant fashion in some families.<sup>
<xref ref-type="bibr" rid="bibr26-0883073811435829">26</xref>
</sup> The spectrum of this syndrome is continuing to expand and includes children with absence epilepsies, myoclonic–astatic epilepsy, paroxysmal neurological disorders, ataxia, and dystonia (nonclassical phenotype).<sup>
<xref ref-type="bibr" rid="bibr24-0883073811435829">24</xref>,<xref ref-type="bibr" rid="bibr27-0883073811435829">27</xref>,<xref ref-type="bibr" rid="bibr28-0883073811435829">28</xref>
</sup> In some cases, the EEG shows epileptiform activity preprandially with resolution postprandially.<sup>
<xref ref-type="bibr" rid="bibr29-0883073811435829">29</xref>,<xref ref-type="bibr" rid="bibr30-0883073811435829">30</xref>
</sup> It is important to recognize this syndrome promptly, as children respond well to the ketogenic diet.<sup>
<xref ref-type="bibr" rid="bibr31-0883073811435829">31</xref>
</sup>
</p>
</sec>
<sec id="section20-0883073811435829">
<title>Mitochondrial Disorders</title>
<p>Mitochondrial disorders are multisystemic disorders resulting from dysfunction of organs that are highly dependent on aerobic metabolism such as brain, heart, and muscle. They are associated with mutations in nuclear DNA encoding mitochondrial proteins and mitochondrial DNA. Seizures are common manifestations of these disorders in general. In this review we focus on a particularly severe phenotype, Alpers syndrome.</p>
<p>Bernard Alpers first described a diffuse progressive degeneration of cerebral gray in 1931. Alpers syndrome is also known as progressive neuronal degeneration of childhood and progressive infantile poliodystrophy. This rare autosomal recessive hepatocerebral disorder starts in infancy or childhood and is characterized by epilepsy (particularly epilepsia partialis continua),<sup>
<xref ref-type="bibr" rid="bibr32-0883073811435829">32</xref>,<xref ref-type="bibr" rid="bibr33-0883073811435829">33</xref>
</sup> developmental regression, hypotonia, ataxia, cortical blindness, and hepatic dysfunction. Typically, a developmentally healthy infant develops myoclonic seizures, generalized seizures, or epilepsia partialis continua in the setting of intercurrent illness.<sup>
<xref ref-type="bibr" rid="bibr34-0883073811435829">34</xref>
</sup> Most cases of Alpers disease are caused by recessive mutations in polymerase γA (<italic>POLG1</italic>), the only polymerase responsible for the synthesis and repair of mitochondrial DNA in mammalian cells. Pol γ is encoded by the nuclear polymerase γA (<italic>POLG1</italic>) gene; mutation of this gene results in profoundly decreased mitochondrial DNA copy numbers in affected tissues.<sup>
<xref ref-type="bibr" rid="bibr35-0883073811435829">35</xref>
<xref ref-type="bibr" rid="bibr36-0883073811435829"/>–<xref ref-type="bibr" rid="bibr37-0883073811435829">37</xref>
</sup>
</p>
<p>There is no specific treatment for Alpers disease. Valproic acid is contraindicated in these patients, as exposure to this medication can precipitate hepatic failure.<sup> </sup>This can manifest several weeks after starting therapy and is often irreversible.<sup>
<xref ref-type="bibr" rid="bibr37-0883073811435829">37</xref>
</sup> The prognosis in Alpers disease is poor. Most patients die by the age of 5 years, although rare survival into early adulthood has been described,<sup>
<xref ref-type="bibr" rid="bibr38-0883073811435829">38</xref>,<xref ref-type="bibr" rid="bibr39-0883073811435829">39</xref>
</sup> as has adult onset. Liver failure and intractable seizures are the most common causes of death.</p>
</sec>
<sec id="section21-0883073811435829">
<title>Creatine Deficiency</title>
<p>Creatine deficiency in the brain is caused by 3 different defects: impaired creatine transporter function (X linked: mutation in the SLC6A8)<sup>
<xref ref-type="bibr" rid="bibr40-0883073811435829">40</xref>,<xref ref-type="bibr" rid="bibr41-0883073811435829">41</xref>
</sup> or impaired creatine synthesis in guanidinoacetate methyltransferase and arginine–glycine amidinotransferase deficiency (both autosomal recessive). Guanidinoacetate methyltransferase deficiency is often associated with intractable epilepsy, whereas all other forms have varying degree of mental retardation, speech delay, and autism.<sup>
<xref ref-type="bibr" rid="bibr42-0883073811435829">42</xref>
</sup> A decreased or absent creatine peak on the MRI of brain and increased excretion of guanidino compounds in the urine help make the diagnosis.<sup>
<xref ref-type="bibr" rid="bibr43-0883073811435829">43</xref>
</sup> No specific EEG pattern has been described. Treatment is based on creatine supplementation in the diet, although the transporter defect is usually poorly responsive.</p>
</sec>
</sec>
<sec id="section22-0883073811435829">
<title>Neuronal Dysfunction Associated With Structural Changes</title>
<p>This section discusses lysosomal storage disorders, disorders of glycogen metabolism, and metabolic disorders associated with brain malformation.</p>
<sec id="section23-0883073811435829">
<title>Lysosomal Storage Disorders</title>
<sec id="section24-0883073811435829">
<title>The neuronal ceroid-lipofuscinoses</title>
<p>Neuronal ceroid-lipofuscinoses are a group of heterogeneous inherited, neurodegenerative, lysosomal-storage disorders characterized by progressive cognitive and motor deterioration, intractable seizures, and early death. Visual loss is a feature of most forms. They are traditionally classified clinically by age of onset and order of appearance of the clinical features into infantile, late-infantile, juvenile, and adult forms. Mutation analysis has shown that these clinical categories are genetically heterogeneous. Myoclonic seizures and visual loss (due to retinal pigment epithelium atrophy) are 2 common features in the different phenotypes.<sup>
<xref ref-type="bibr" rid="bibr44-0883073811435829">44</xref>
</sup> Brain neuroimaging shows progressive atrophy. The diagnosis of neuronal ceroid-lipofuscinoses is often based on assay of enzyme activity and/or molecular genetic testing and, in some instances, on electron microscopy of biopsied tissues or white blood cells.<sup>
<xref ref-type="bibr" rid="bibr45-0883073811435829">45</xref>,<xref ref-type="bibr" rid="bibr46-0883073811435829">46</xref>
</sup> There is neural and extraneural accumulation of ceroid- and lipofuscin-like autofluorescent storage material forming characteristic inclusions with limited specificity: granular osmiophilic deposits, curvilinear bodies, and fingerprint bodies. Molecular genetic testing for the genes known to be associated with neuronal ceroid-lipofuscinoses—<italic>PPT1</italic>, <italic>TPP1</italic>, <italic>CLN3</italic>, <italic>CLN5</italic>, <italic>CLN6</italic>, <italic>MFSD8</italic>,<italic> CLN8</italic>, <italic>CTSD</italic>,<italic> DNAJC5</italic>—is clinically available.<sup>
<xref ref-type="bibr" rid="bibr47-0883073811435829">47</xref>
<xref ref-type="bibr" rid="bibr48-0883073811435829"/>
<xref ref-type="bibr" rid="bibr49-0883073811435829"/>–<xref ref-type="bibr" rid="bibr50-0883073811435829">50</xref> </sup>Electroencephalogram may show photosensitivity at low frequency stimulation and spike and slow waves in some forms. Seizures are often intractable, and management is mostly symptomatic.<sup>
<xref ref-type="bibr" rid="bibr48-0883073811435829">48</xref>,<xref ref-type="bibr" rid="bibr51-0883073811435829">51</xref>
</sup>
</p>
</sec>
<sec id="section25-0883073811435829">
<title>Gangliosidoses</title>
<p>Gangliosidoses are a group of lysosomal storage diseases caused by enzyme deficiencies leading to accumulation of gangliosides (glycosphingolipids containing varying amounts of monosaccharides and sialic acid that occur at high concentration in neurons) in multiple organs including the brain. Tay Sachs (hexosaminidase A deficiency, GM2 gangliosidosis) was the most common phenotype prior to the institution of screening in the Ashkenazi population. Seizures are common and reflect the primary involvement of gray matter in these disorders and the phenomenon of ectopic dendritogenesis that is associated with the accumulation of GM2 ganglioside in several storage disorders in addition to GM2 gangliosidosis.<sup>
<xref ref-type="bibr" rid="bibr52-0883073811435829">52</xref>,<xref ref-type="bibr" rid="bibr53-0883073811435829">53</xref>
</sup> Typical features include progressive neurodegeneration with cognitive decline, seizures, movement disorder, spasticity, cherry red spot on funduscopy in some forms, and early death. Organomegaly is absent in Tay-Sachs disease but is often present in other forms of GM2 and in GM1 gangliosidoses. No particular seizure type or EEG pattern is specific to these disorders. Treatment is usually supportive, and any of the conventional antiepileptics can be tried.</p>
</sec>
<sec id="section26-0883073811435829">
<title>Gaucher disease</title>
<p>Gaucher disease results from deficiency of lysosomal enzyme glucocerebrosidase. Type 2 (typically acute presentation) and 3 (typically chronic presentation) are neuropathic forms, and seizures are part of the neurodegenerative process. Type 2 can have prenatal or perinatal onset. In both forms patients develop progressive spasticity, opisthotonus, bulbar involvement, and seizures; type 3 may present as a progressive myoclonic dementia in older children and adolescents, particularly in the genetic isolates from northern Sweden (Norrbottnian type).<sup>
<xref ref-type="bibr" rid="bibr54-0883073811435829">54</xref>
</sup>
</p>
</sec>
<sec id="section27-0883073811435829">
<title>Niemann-Pick disease</title>
<p>Niemann-Pick disease embraces a family of 2 genetically distinct disorders. The first subgroup is associated with primary deficiency of acid sphingomyelinase. This leads to progressive deposition of sphingomyelin mainly in the reticuloendothelial cells. These are traditionally subdivided into groups A and B that are allelic disorders. The former is characterized by rapid neurodegeneration and organomegaly (neuropathic form), the latter by organomegaly without primary neurological involvement (nonneuropathic form).<sup>
<xref ref-type="bibr" rid="bibr55-0883073811435829">55</xref>
</sup> The second subgroup is classified as Niemann-Pick disease, type C. This disorder is a result of mutations in 2 separate genes that regulate endosomal–lysosomal trafficking. Niemann-Pick disease, type C, is characterized by neurodegeneration.<sup>
<xref ref-type="bibr" rid="bibr56-0883073811435829">56</xref>
</sup> Thus, seizures reflect the poliodystrophy of Niemann-Pick types A and C.</p>
</sec>
</sec>
<sec id="section28-0883073811435829">
<title>Disorders of Glycogen Metabolism</title>
<sec id="section29-0883073811435829">
<title>Lafora body disease</title>
<p>Lafora body disease is an autosomal recessive disease characterized by fragmentary or generalized myoclonus and/or generalized tonic–clonic seizures, visual hallucinations (representing occipital seizures in some cases),<sup>
<xref ref-type="bibr" rid="bibr57-0883073811435829">57</xref>
</sup> and progressive neurological degeneration including cognitive deterioration, dysarthria, and ataxia beginning in previously healthy children in the second decade. Most affected individuals die within 10 years of onset, usually from status epilepticus or from complications related to neurodegeneration. Diagnosis is usually based on clinical and EEG findings (slow background, paroxysms of generalized irregular spike-wave discharges with occipital predominance)<sup>
<xref ref-type="bibr" rid="bibr58-0883073811435829">58</xref>,<xref ref-type="bibr" rid="bibr59-0883073811435829">59</xref>
</sup> and detection of 2 mutations in 1 of the 2 genes known to be associated with Lafora body disease: <italic>EPM2A</italic> or <italic>NHLRC1(EPM2B</italic>).<sup>
<xref ref-type="bibr" rid="bibr60-0883073811435829">60</xref>,<xref ref-type="bibr" rid="bibr61-0883073811435829">61</xref>
</sup> The details of the biochemical pathway of glycogen metabolism that is disturbed in this disorder remain incomplete. Occasionally, skin biopsy of eccrine or apocrine sweat glands to detect pathognomonic intracellular Lafora bodies (polyglucosan bodies) is necessary to confirm the diagnosis.<sup>
<xref ref-type="bibr" rid="bibr62-0883073811435829">62</xref>
</sup> Treatment is symptomatic with antiepileptics. A pilot study of ketogenic diet in this population was not promising.<sup>
<xref ref-type="bibr" rid="bibr63-0883073811435829">63</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section30-0883073811435829">
<title>Metabolic Disorders Associated With Brain Malformation</title>
<sec id="section31-0883073811435829">
<title>Peroxisomal disorders</title>
<p>These disorders can be divided into 2 categories: disorders of peroxisome biogenesis and single enzyme defects. Many of these disorders are associated with abnormal neuronal migration, as peroxisomes play an important role in neuronal migration in developing cerebral cortex and cerebellum, neuronal differentiation, proliferation, and survival.<sup>
<xref ref-type="bibr" rid="bibr64-0883073811435829">64</xref>
</sup> Zellweger syndrome, the prototype of peroxisomal disorders, features pachygyria and polymicrogyria localized to the opercular region. The clinical presentation includes profound hypotonia, characteristic craniofacial dysmorphism (high forehead, large anterior fontanel), organomegaly, and seizures.<sup>
<xref ref-type="bibr" rid="bibr65-0883073811435829">65</xref>
</sup>
</p>
</sec>
<sec id="section32-0883073811435829">
<title>Congenital disorders of glycosylation</title>
<p>Three disorders of O-linked glycosylation cause congenital muscular dystrophies (Walker-Warburg syndrome, muscle–eye–brain disease, Fukuyama muscular dystrophy) that combine muscle pathological changes with brain malformations ranging from lissencephaly to pachygyria and polymicrogyria. These malformations are manifest as developmental delay and seizures, which are often intractable. Electroencephalogram may show excessive β activity in addition to epileptiform discharges.<sup>
<xref ref-type="bibr" rid="bibr66-0883073811435829">66</xref>,<xref ref-type="bibr" rid="bibr67-0883073811435829">67</xref>
</sup>
</p>
<p>Defects in N-linked glycosylation present with protean manifestations that may sometimes mimic mitochondrial disorders but lack a history of maternal inheritance. They typically manifest a combination of liver, gastrointestinal, and coagulation disorders. These disorders should be investigated in any child presenting with developmental delay, seizures, and multisystemic involvement. Lipoatrophy, inverted nipples, and esotropia are common findings on physical examination, whereas cerebellar atrophy is frequently seen on neuroimaging.<sup>
<xref ref-type="bibr" rid="bibr68-0883073811435829">68</xref>,<xref ref-type="bibr" rid="bibr69-0883073811435829">69</xref>
</sup>
</p>
</sec>
</sec>
</sec>
<sec id="section33-0883073811435829">
<title>Conclusion</title>
<p>Seizures and other neurological manifestations are common manifestations of inborn errors of metabolism, and neurologists must be aware of these disorders to provide optimum care to affected children and their families. A systematic approach is the key to early diagnosis of inborn error of metabolisms. Early diagnosis is important both to initiate disease-modifying treatment promptly and to offer genetic counseling to offer parents the opportunity to plan their families with accurate knowledge of the risks of conceiving affected children in the future.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn1-0883073811435829">
<p>Dr Dhamija drafted the original manuscript and Drs Patterson and Wirrell provided extensive editorial comments.</p>
</fn>
<fn fn-type="conflict" id="fn2-0883073811435829">
<p>Dr Dhamija reports no conflicts of interest or commercial/other financial relationships. Dr Patterson: Actelion Pharmaceuticals: research grants, travel expenses, consulting honoraria directed to Mayo Clinic. Shire Human Genetic Therapies: travel expenses, consulting honoraria directed to Mayo Clinic. Stem Cells, Inc: chair, Data Monitoring Committee, honorarium retained. Up-To-Date: section editor, royalties retained. <italic>Journal of Child Neurology</italic>: editorial board (no compensation). WHO International Advisory Group on revision of ICD-10: ICNA representative (no compensation). IOM Committee to Review Adverse Effects of Vaccines: member (no compensation). Dr Wirrell serves on the editorial boards for <italic>Epilepsia</italic>, <italic>Canadian Journal of Neurological Sciences</italic>, and <italic>Journal of Child Neurology</italic>.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0883073811435829">
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073811435829">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Applegarth</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Toone</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Lowry</surname>
<given-names>RB</given-names>
</name>
</person-group>. <article-title>Incidence of inborn errors of metabolism in British Columbia, 1969-1996</article-title>. <source>Pediatrics</source>. <year>2000</year>;<volume>105</volume>: <fpage>e10</fpage>.</citation>
</ref>
<ref id="bibr2-0883073811435829">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meikle</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Hopwood</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Clague</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>WF</given-names>
</name>
</person-group>. <article-title>Prevalence of lysosomal storage disorders</article-title>. <source>JAMA</source>. <year>1999</year>;<volume>281</volume>:<fpage>249</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr3-0883073811435829">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burin</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Scholz</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Gus</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Investigation of lysosomal storage diseases in nonimmune hydrops fetalis</article-title>. <source>Prenat Diagn</source>. <year>2004</year>;<volume>24</volume>:<fpage>653</fpage>–<lpage>657</lpage>.</citation>
</ref>
<ref id="bibr4-0883073811435829">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gropman</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Summar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>JV</given-names>
</name>
</person-group>. <article-title>Neurological implications of urea cycle disorders</article-title>. <source>J Inherit Metab Dis</source>. <year>2007</year>;<volume>30</volume>:<fpage>865</fpage>–<lpage>879</lpage>.</citation>
</ref>
<ref id="bibr5-0883073811435829">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kure</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Oota</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hino</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fukuda</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Nonketotic hyperglycinemia: proposal of a diagnostic and treatment strategy</article-title>. <source>Pediatr Neurol</source>. <year>2010</year>;<volume>43</volume>:<fpage>221</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr6-0883073811435829">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mourmans</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Majoie</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Barth</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Duran</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Akkerman</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Poll-The</surname>
<given-names>BT</given-names>
</name>
</person-group>. <article-title>Sequential MR imaging changes in nonketotic hyperglycinemia</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>2006</year>;<volume>27</volume>:<fpage>208</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr7-0883073811435829">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Hove</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Vande Kerckhove</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hennermann</surname>
<given-names>JB</given-names>
</name>
<etal/>
</person-group> <article-title>Benzoate treatment and the glycine index in nonketotic hyperglycinaemia</article-title>. <source>J Inherit Metab Dis</source>. <year>2005</year>;<volume>28</volume>:<fpage>651</fpage>–<lpage>663</lpage>.</citation>
</ref>
<ref id="bibr8-0883073811435829">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deodato</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Boenzi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Santorelli</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Dionisi-Vici</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Methylmalonic and propionic aciduria</article-title>. <source>Am J Med Genet C Semin Med Genet</source>. <year>2006</year>;<volume>142C</volume>:<fpage>104</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr9-0883073811435829">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agarwal</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Muranjan</surname>
<given-names>MN</given-names>
</name>
</person-group>. <article-title>Diagnostic practice for organic acidemias: barriers to early diagnosis</article-title>. <source>Arch Dis Child</source>. <year>2008</year>;<volume>93</volume>:<fpage>1000</fpage>.</citation>
</ref>
<ref id="bibr10-0883073811435829">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bunch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Peculiar neuroimaging and electrophysiological findings in a patient with biotinidase deficiency</article-title>. <source>Seizure</source>. <year>2011</year>;<volume>20</volume>:<fpage>83</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr11-0883073811435829">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singhi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Ohtahara syndrome with biotinidase deficiency</article-title>. <source>J Child Neurol</source>. <year>2011</year>;<volume>26</volume>:<fpage>507</fpage>–<lpage>509</lpage>.</citation>
</ref>
<ref id="bibr12-0883073811435829">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sowell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pollard</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Quantification of branched-chain amino acids in blood spots and plasma by liquid chromatography tandem mass spectrometry for the diagnosis of maple syrup urine disease</article-title>. <source>J Sep Sci</source>. <year>2011</year>;<volume>34</volume>:<fpage>631</fpage>–<lpage>639</lpage>.</citation>
</ref>
<ref id="bibr13-0883073811435829">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>WT</given-names>
</name>
</person-group>. <article-title>Disorders of amino acid metabolism associated with epilepsy</article-title>. <source>Brain Dev</source>. <year>2011</year>;<volume>33</volume>:<fpage>745</fpage>–<lpage>752</lpage>.</citation>
</ref>
<ref id="bibr14-0883073811435829">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mills</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Struys</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jakobs</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Mutations in antiquitin in individuals with pyridoxine-dependent seizures</article-title>. <source>Nat Med</source>. <year>2006</year>;<volume>12</volume>:<fpage>307</fpage>–<lpage>309</lpage>.</citation>
</ref>
<ref id="bibr15-0883073811435829">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitt</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Baumgartner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>PB</given-names>
</name>
<etal/>
</person-group> <article-title>Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency</article-title>. <source>Dev Med Child Neurol</source>. <year>2010</year>;<volume>52</volume>: <fpage>e133</fpage>–<lpage>e142</lpage>.</citation>
</ref>
<ref id="bibr16-0883073811435829">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gospe</surname>
<given-names>SM</given-names>
<suffix> Jr</suffix>
</name>
</person-group>. <article-title>Pyridoxine-dependent seizures: new genetic and biochemical clues to help with diagnosis and treatment</article-title>. <source>Curr Opin Neurol</source>. <year>2006</year>;<volume>19</volume>:<fpage>148</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr17-0883073811435829">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baynes</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Farias</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Gospe</surname>
<given-names>SM</given-names> <suffix>Jr</suffix>
</name>
</person-group>. <article-title>Pyridoxine-dependent seizures and cognition in adulthood</article-title>. <source>Dev Med Child Neurol</source>. <year>2003</year>;<volume>45</volume>:<fpage>782</fpage>–<lpage>785</lpage>.</citation>
</ref>
<ref id="bibr18-0883073811435829">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khayat</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Korman</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Frankel</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>PNPO deficiency: an under diagnosed inborn error of pyridoxine metabolism</article-title>. <source>Mol Genet Metab</source>. <year>2008</year>;<volume>94</volume>:<fpage>431</fpage>–<lpage>434</lpage>.</citation>
</ref>
<ref id="bibr19-0883073811435829">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mills</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Surtees</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Champion</surname>
<given-names>MP</given-names>
</name>
<etal/>
</person-group> <article-title>Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5′-phosphate oxidase</article-title>. <source>Hum Mol Genet</source>. <year>2005</year>;<volume>14</volume>:<fpage>1077</fpage>–<lpage>1086</lpage>.</citation>
</ref>
<ref id="bibr20-0883073811435829">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bagci</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zschocke</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>GF</given-names>
</name>
<etal/>
</person-group> <article-title>Pyridoxal phosphate-dependent neonatal epileptic encephalopathy</article-title>. <source>Arch Dis Child Fetal Neonatal Ed</source>. <year>2008</year>;<volume>93</volume>: <fpage>F151</fpage>–<lpage>F152</lpage>.</citation>
</ref>
<ref id="bibr21-0883073811435829">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruiz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Garcia-Villoria</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ormazabal</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>A new fatal case of pyridox(am)ine 5′-phosphate oxidase (PNPO) deficiency</article-title>. <source>Mol Genet Metab</source>. <year>2008</year>;<volume>93</volume>:<fpage>216</fpage>–<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr22-0883073811435829">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallagher</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Van Hove</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Scharer</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy</article-title>. <source>Ann Neurol</source>. <year>2009</year>;<volume>65</volume>:<fpage>550</fpage>–<lpage>556</lpage>.</citation>
</ref>
<ref id="bibr23-0883073811435829">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manegold</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Degen</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group> <article-title>Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up</article-title>. <source>J Inherit Metab Dis</source>. <year>2009</year>;<volume>32</volume>:<fpage>371</fpage>–<lpage>380</lpage>.</citation>
</ref>
<ref id="bibr24-0883073811435829">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mullen</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Suls</surname>
<given-names>A</given-names>
</name>
<name>
<surname>De Jonghe</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Berkovic</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Scheffer</surname>
<given-names>IE</given-names>
</name>
</person-group>. <article-title>Absence epilepsies with widely variable onset are a key feature of familial GLUT1 deficiency</article-title>. <source>Neurology</source>. <year>2010</year>;<volume>75</volume>:<fpage>432</fpage>–<lpage>440</lpage>.</citation>
</ref>
<ref id="bibr25-0883073811435829">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Vivo</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Leary</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Glucose transporter 1 deficiency syndrome and other glycolytic defects</article-title>. <source>J Child Neurol</source>. <year>2002</year>;<volume>17</volume>(<issue>suppl 3</issue>):<fpage>3S15</fpage>–<lpage>3S23</lpage>; <comment>discussion 3S24-3S25</comment>.</citation>
</ref>
<ref id="bibr26-0883073811435829">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leen</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Klepper</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Verbeek</surname>
<given-names>MM</given-names>
</name>
<etal/>
</person-group> <article-title>Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder</article-title>. <source>Brain</source>. <year>2010</year>;<volume>133</volume>:<fpage>655</fpage>–<lpage>670</lpage>.</citation>
</ref>
<ref id="bibr27-0883073811435829">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leary</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nordli</surname>
<given-names>DR</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Engelstad</surname>
<given-names>K</given-names>
</name>
<name>
<surname>De Vivo</surname>
<given-names>DC</given-names>
</name>
</person-group>. <article-title>Seizure characterization and electroencephalographic features in Glut-1 deficiency syndrome</article-title>. <source>Epilepsia</source>. <year>2003</year>;<volume>44</volume>:<fpage>701</fpage>–<lpage>707</lpage>.</citation>
</ref>
<ref id="bibr28-0883073811435829">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suls</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mullen</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>YG</given-names>
</name>
<etal/>
</person-group> <article-title>Early-onset absence epilepsy caused by mutations in the glucose transporter GLUT1</article-title>. <source>Ann Neurol</source>. <year>2009</year>;<volume>66</volume>:<fpage>415</fpage>–<lpage>419</lpage>.</citation>
</ref>
<ref id="bibr29-0883073811435829">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>von Moers</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brockmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>EEG features of glut-1 deficiency syndrome</article-title>. <source>Epilepsia</source>. <year>2002</year>;<volume>43</volume>:<fpage>941</fpage>–<lpage>945</lpage>.</citation>
</ref>
<ref id="bibr30-0883073811435829">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parolin</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Drigo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Toldo</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group> <article-title>Pre- and postprandial electroencephalography in glucose transporter type 1 deficiency syndrome: an illustrative case to discuss the concept of carbohydrate responsiveness</article-title>. <source>J Child Neurol</source>. <year>2011</year>;<volume>26</volume>:<fpage>103</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr31-0883073811435829">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klepper</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Diefenbach</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kohlschutter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Voit</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Effects of the ketogenic diet in the glucose transporter 1 deficiency syndrome</article-title>. <source>Prostaglandins Leukot Essent Fatty Acids</source>. <year>2004</year>;<volume>70</volume>:<fpage>321</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr32-0883073811435829">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolf</surname>
<given-names>NI</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group> <article-title>Status epilepticus in children with Alpers’ disease caused by POLG1 mutations: EEG and MRI features</article-title>. <source>Epilepsia</source>. <year>2009</year>;<volume>50</volume>:<fpage>1596</fpage>–<lpage>1607</lpage>.</citation>
</ref>
<ref id="bibr33-0883073811435829">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCoy</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Owens</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Howley</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Partial status epilepticus—rapid genetic diagnosis of Alpers’ disease</article-title>. <source>Eur J Paediatr Neurol</source>. <year>2011</year>;<volume>15</volume>:<fpage>558</fpage>–<lpage>562</lpage>.</citation>
</ref>
<ref id="bibr34-0883073811435829">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordon</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Alpers syndrome: progressive neuronal degeneration of children with liver disease</article-title>. <source>Dev Med Child Neurol</source>. <year>2006</year>;<volume>48</volume>:<fpage>1001</fpage>–<lpage>1003</lpage>.</citation>
</ref>
<ref id="bibr35-0883073811435829">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naviaux</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>KV</given-names>
</name>
</person-group>. <article-title>POLG mutations associated with Alpers syndrome and mitochondrial DNA depletion</article-title>. <source>Ann Neurol</source>. <year>2005</year>;<volume>58</volume>:<fpage>491</fpage>.</citation>
</ref>
<ref id="bibr36-0883073811435829">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>Sharief</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Copeland</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Naviaux</surname>
<given-names>RK</given-names>
</name>
</person-group>. <article-title>Molecular diagnosis of Alpers syndrome</article-title>. <source>J Hepatol</source>. <year>2006</year>;<volume>45</volume>:<fpage>108</fpage>–<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr37-0883073811435829">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engelsen</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Tzoulis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Karlsen</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group> <article-title>POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection</article-title>. <source>Brain</source>. <year>2008</year>;<volume>131</volume>:<fpage>818</fpage>–<lpage>828</lpage>.</citation>
</ref>
<ref id="bibr38-0883073811435829">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiltshire</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Davidzon</surname>
<given-names>G</given-names>
</name>
<name>
<surname>DiMauro</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Juvenile Alpers disease</article-title>. <source>Arch Neurol</source>. <year>2008</year>;<volume>65</volume>:<fpage>121</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr39-0883073811435829">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Visser</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>van den Bergh</surname>
<given-names>WM</given-names>
</name>
<etal/>
</person-group> <article-title>Juvenile-onset Alpers syndrome: interpreting MRI findings</article-title>. <source>Neurology</source>. <year>2010</year>;<volume>74</volume>:<fpage>1231</fpage>–<lpage>1233</lpage>.</citation>
</ref>
<ref id="bibr40-0883073811435829">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bizzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bugiani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Salomons</surname>
<given-names>GS</given-names>
</name>
<etal/>
</person-group> <article-title>X-linked creatine deficiency syndrome: a novel mutation in creatine transporter gene SLC6A8</article-title>. <source>Ann Neurol</source>. <year>2002</year>;<volume>52</volume>:<fpage>227</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr41-0883073811435829">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salomons</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>van Dooren</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Verhoeven</surname>
<given-names>NM</given-names>
</name>
<etal/>
</person-group> <article-title>X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome</article-title>. <source>Am J Hum Genet</source>. <year>2001</year>;<volume>68</volume>:<fpage>1497</fpage>–<lpage>1500</lpage>.</citation>
</ref>
<ref id="bibr42-0883073811435829">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nasrallah</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Feki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaabachi</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Creatine and creatine deficiency syndromes: biochemical and clinical aspects</article-title>. <source>Pediatr Neurol</source>. <year>2010</year>;<volume>42</volume>:<fpage>163</fpage>–<lpage>171</lpage>.</citation>
</ref>
<ref id="bibr43-0883073811435829">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nasrallah</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Feki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Briand</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kaabachi</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>GC/MS determination of guanidinoacetate and creatine in urine: a routine method for creatine deficiency syndrome diagnosis</article-title>. <source>Clin Biochem</source>. <year>2010</year>;<volume>43</volume>:<fpage>1356</fpage>–<lpage>1361</lpage>.</citation>
</ref>
<ref id="bibr44-0883073811435829">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hainsworth</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>GT</given-names>
</name>
<name>
<surname>Hamm</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>ML</given-names>
</name>
</person-group>. <article-title>Funduscopic and angiographic appearance in the neuronal ceroid lipofuscinoses</article-title>. <source>Retina</source>. <year>2009</year>;<volume>29</volume>:<fpage>657</fpage>–<lpage>668</lpage>.</citation>
</ref>
<ref id="bibr45-0883073811435829">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goebel</surname>
<given-names>HH</given-names>
</name>
</person-group>. <article-title>Morphological aspects of the neuronal ceroid lipofuscinoses</article-title>. <source>Neurol Sci</source>. <year>2000</year>;<volume>21</volume>: <fpage>S27</fpage>–<lpage>S33</lpage>.</citation>
</ref>
<ref id="bibr46-0883073811435829">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Aberg</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Autti</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Goebel</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Kohlschutter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lonnqvist</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Diagnosis of the neuronal ceroid lipofuscinoses: an update</article-title>. <source>Biochim Biophys Acta</source>. <year>2006</year>;<volume>1762</volume>:<fpage>865</fpage>–<lpage>872</lpage>.</citation>
</ref>
<ref id="bibr47-0883073811435829">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mole</surname>
<given-names>SE</given-names>
</name>
</person-group>. <article-title>The genetic spectrum of human neuronal ceroid-lipofuscinoses</article-title>. <source>Brain Pathol</source>. <year>2004</year>;<volume>14</volume>:<fpage>70</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr48-0883073811435829">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goebel</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Wisniewski</surname>
<given-names>KE</given-names>
</name>
</person-group>. <article-title>Current state of clinical and morphological features in human NCL</article-title>. <source>Brain Pathol</source>. <year>2004</year>;<volume>14</volume>:<fpage>61</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr49-0883073811435829">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noskova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Stranecky</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hartmannova</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group> <article-title>Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis</article-title>. <source>Am J Hum Genet</source>. <year>2011</year>;<volume>89</volume>:<fpage>241</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr50-0883073811435829">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arsov</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Damiano</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6</article-title>. <source>Am J Hum Genet</source>. <year>2011</year>;<volume>88</volume>:<fpage>566</fpage>–<lpage>573</lpage>.</citation>
</ref>
<ref id="bibr51-0883073811435829">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kohlschutter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Towards understanding the neuronal ceroid lipofuscinoses</article-title>. <source>Brain Dev</source>. <year>2009</year>;<volume>31</volume>:<fpage>499</fpage>–<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr52-0883073811435829">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walkley</surname>
<given-names>SU</given-names>
</name>
<name>
<surname>Vanier</surname>
<given-names>MT</given-names>
</name>
</person-group>. <article-title>Secondary lipid accumulation in lysosomal disease</article-title>. <source>Biochim Biophys Acta</source>. <year>2009</year>;<volume>1793</volume>:<fpage>726</fpage>–<lpage>736</lpage>.</citation>
</ref>
<ref id="bibr53-0883073811435829">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walkley</surname>
<given-names>SU</given-names>
</name>
</person-group>. <article-title>Secondary accumulation of gangliosides in lysosomal storage disorders</article-title>. <source>Semin Cell Dev Biol</source>. <year>2004</year>;<volume>15</volume>:<fpage>433</fpage>–<lpage>444</lpage>.</citation>
</ref>
<ref id="bibr54-0883073811435829">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Oppenheim</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Kauvar</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Tayebi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sidransky</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity</article-title>. <source>Blood Cells Mol Dis</source>. <year>2011</year>;<volume>46</volume>:<fpage>75</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr55-0883073811435829">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuchman</surname>
<given-names>EH</given-names>
</name>
</person-group>. <article-title>The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease</article-title>. <source>J Inherit Metab Dis</source>. <year>2007</year>;<volume>30</volume>:<fpage>654</fpage>–<lpage>663</lpage>.</citation>
</ref>
<ref id="bibr56-0883073811435829">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanier</surname>
<given-names>MT</given-names>
</name>
</person-group>. <article-title>Niemann-Pick disease type C</article-title>. <source>Orphanet J Rare Dis</source>. <year>2010</year>;<volume>5</volume>:<fpage>16</fpage>.</citation>
</ref>
<ref id="bibr57-0883073811435829">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andrade</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>del Campo</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Moro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Minassian</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Wennberg</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Nonepileptic visual hallucinations in Lafora disease</article-title>. <source>Neurology</source>. <year>2005</year>;<volume>64</volume>:<fpage>1311</fpage>–<lpage>1312</lpage>.</citation>
</ref>
<ref id="bibr58-0883073811435829">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Driver-Dunkley</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sirven</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Drazkowski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Caviness</surname>
<given-names>JN</given-names>
</name>
</person-group>. <article-title>Lafora disease with primary generalized epileptic myoclonus</article-title>. <source>Mov Disord</source>. <year>2005</year>;<volume>20</volume>:<fpage>907</fpage>–<lpage>908</lpage>.</citation>
</ref>
<ref id="bibr59-0883073811435829">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Beydoun</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Drury</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Longitudinal EEG studies in a kindred with Lafora disease</article-title>. <source>Epilepsia</source>. <year>1991</year>;<volume>32</volume>:<fpage>895</fpage>–<lpage>899</lpage>.</citation>
</ref>
<ref id="bibr60-0883073811435829">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lesca</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Boutry-Kryza</surname>
<given-names>N</given-names>
</name>
<name>
<surname>de Toffol</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group> <article-title>Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease</article-title>. <source>Epilepsia</source>. <year>2010</year>;<volume>51</volume>:<fpage>1691</fpage>–<lpage>1698</lpage>.</citation>
</ref>
<ref id="bibr61-0883073811435829">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lohi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Turnbull</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>XC</given-names>
</name>
<etal/>
</person-group> <article-title>Genetic diagnosis in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls</article-title>. <source>Neurology</source>. <year>2007</year>;<volume>68</volume>:<fpage>996</fpage>–<lpage>1001</lpage>.</citation>
</ref>
<ref id="bibr62-0883073811435829">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andrade</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Ackerley</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Minett</surname>
<given-names>TS</given-names>
</name>
<etal/>
</person-group> <article-title>Skin biopsy in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls</article-title>. <source>Neurology</source>. <year>2003</year>;<volume>61</volume>:<fpage>1611</fpage>–<lpage>1614</lpage>.</citation>
</ref>
<ref id="bibr63-0883073811435829">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardinali</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Canafoglia</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bertoli</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>A pilot study of a ketogenic diet in patients with Lafora body disease</article-title>. <source>Epilepsy Res</source>. <year>2006</year>;<volume>69</volume>:<fpage>129</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr64-0883073811435829">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faust</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Banka</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Siriratsivawong</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Wikander</surname>
<given-names>TM</given-names>
</name>
</person-group>. <article-title>Peroxisome biogenesis disorders: the role of peroxisomes and metabolic dysfunction in developing brain</article-title>. <source>J Inherit Metab Dis</source>. <year>2005</year>;<volume>28</volume>:<fpage>369</fpage>–<lpage>383</lpage>.</citation>
</ref>
<ref id="bibr65-0883073811435829">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinberg</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Dodt</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Raymond</surname>
<given-names>GV</given-names>
</name>
<name>
<surname>Braverman</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Moser</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Moser</surname>
<given-names>HW</given-names>
</name>
</person-group>. <article-title>Peroxisome biogenesis disorders</article-title>. <source>Biochim Biophys Acta</source>. <year>2006</year>;<volume>1763</volume>:<fpage>1733</fpage>–<lpage>1748</lpage>.</citation>
</ref>
<ref id="bibr66-0883073811435829">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grewal</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Hewitt</surname>
<given-names>JE</given-names>
</name>
</person-group>. <article-title>Glycosylation defects: a new mechanism for muscular dystrophy?</article-title> <source>Hum Mol Genet</source>. <year>2003</year>;<volume>12</volume>(<issue>spec no 2</issue>): <fpage>R259</fpage>–<lpage>R264</lpage>.</citation>
</ref>
<ref id="bibr67-0883073811435829">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hewitt</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Grewal</surname>
<given-names>PK</given-names>
</name>
</person-group>. <article-title>Glycosylation defects in inherited muscle disease</article-title>. <source>Cell Mol Life. Sci</source>. <year>2003</year>;<volume>60</volume>:<fpage>251</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr68-0883073811435829">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Theodore</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Morava</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Congenital disorders of glycosylation: sweet news</article-title>. <source>Curr Opin Pediatr</source>. <year>2011</year>;<volume>23</volume>:<fpage>581</fpage>–<lpage>587</lpage>.</citation>
</ref>
<ref id="bibr69-0883073811435829">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaeken</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Congenital disorders of glycosylation</article-title>. <source>Ann N Y Acad Sci</source>. <year>2010</year>;<volume>1214</volume>:<fpage>190</fpage>–<lpage>198</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>